Molecular pathology of breast cancer: what a pathologist needs to know
- PMID: 23161709
- DOI: 10.1309/AJCPIV9IQ1MRQMOO
Molecular pathology of breast cancer: what a pathologist needs to know
Abstract
Pathologists are now more than ever "diagnostic oncologists" and serve a critical role as clinical consultants on the biology of disease. In the last decade and a half, molecular information has transformed our thinking about the biologic diversity of breast cancers and redirected the way clinical treatment decisions are made. A basic understanding of the current molecular classification of breast cancers and the biologic pathways from precursors to invasive disease is key to both informing diagnostic practice and serving as clinical consultants. In addition, both single-marker and panel-based molecular tests are currently being utilized in breast cancer tissue to predict the benefit of specific therapies such as HER2-targeted biologic therapy and chemotherapy. Familiarity with the current issues involving these molecular tests as well as the pathologist's role in ensuring appropriate tissue handling, tissue selection, and results interpretation and correlation are paramount to providing optimal patient care.
Similar articles
-
Molecular Testing and the Pathologist's Role in Clinical Trials of Breast Cancer.Clin Breast Cancer. 2016 Jun;16(3):166-79. doi: 10.1016/j.clbc.2016.02.016. Epub 2016 Feb 12. Clin Breast Cancer. 2016. PMID: 27103546 Review.
-
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Cancer Treat Rev. 2012. PMID: 22178455 Review.
-
Adjuvant therapy for breast cancer.NIH Consens Statement. 2000 Nov 1-3;17(4):1-35. NIH Consens Statement. 2000. PMID: 11512506 Review.
-
A pathologist's perspective on emerging genomic tests for breast cancer.Semin Oncol. 2007 Apr;34(2 Suppl 3):S4-9. doi: 10.1053/j.seminoncol.2007.03.016. Semin Oncol. 2007. PMID: 17512433 Review.
-
Pathological parameters useful in predicting prognosis for patients with breast cancer.Monogr Pathol. 1984;(25):175-85. Monogr Pathol. 1984. PMID: 6377048 Review.
Cited by
-
Genetics and Breast Cancer - Oncologists Perspectives.Indian J Surg Oncol. 2015 Dec;6(4):415-9. doi: 10.1007/s13193-016-0491-7. Epub 2016 Jan 13. Indian J Surg Oncol. 2015. PMID: 27065667 Free PMC article. Review.
-
Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer.Oncol Lett. 2018 Sep;16(3):3726-3734. doi: 10.3892/ol.2018.9091. Epub 2018 Jul 5. Oncol Lett. 2018. PMID: 30127983 Free PMC article.
-
Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26.Cancer Med. 2019 Aug;8(9):4176-4188. doi: 10.1002/cam4.2323. Epub 2019 Jun 14. Cancer Med. 2019. PMID: 31199586 Free PMC article.
-
Long non-coding RNA SNHG1 activates HOXA1 expression via sponging miR-193a-5p in breast cancer progression.Aging (Albany NY). 2020 Jun 3;12(11):10223-10234. doi: 10.18632/aging.103123. Epub 2020 Jun 3. Aging (Albany NY). 2020. PMID: 32497022 Free PMC article.
-
Emerging Molecular Technology in Cancer Testing.EJIFCC. 2024 Oct 30;35(3):142-153. eCollection 2024 Oct. EJIFCC. 2024. PMID: 39507577 Free PMC article. Review. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous